About: The efficacy of convalescent plasma for the treatment of severe influenza

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The efficacy of convalescent plasma for the treatment of severe influenza Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The efficacy of convalescent plasma for the treatment of severe influenza
Creator	Li, Yimin Liu, Xiaoqing Liu, Dongdong Xu, Zhiheng Chen, Sibei Huang, Yongbo Lin, Zhimin Liu, Xuesong Xu, Yonghao Zhou, Jianmeng
Source	MedRxiv
abstract	Background. Administration of convalescent plasma may be of clinical benefit for treatment of severe acute viral respiratory infections. However, no clear evidence exists to support or oppose convalescent plasma use in clinical practice. We conducted a systematic review and meta-analysis to assess the evidence of randomized controlled trials (RCTs) in the convalescent plasma for the treatment of severe influenza. Methods. Healthcare databases were searched in February 2020. All records were screened against the eligibility criteria. Data extraction and risk of bias assessments were undertaken. The primary outcome was case fatality rates by influenza. Results. We identified 5 RCTs of severe influenza. The pooled analyses showed no evidence for a reduction in mortality (Odds Ratio (OR) 1.06; p = 0.87; I2 = 35%). We also found non significant reductions in days in ICU and hospital, and days on mechanical ventilation. There seemed to have a biological benefit of increasing HAI titer levels and decreasing influenza B virus loads and cytokines after convalescent plasma treatment. No serious adverse events was reported between two groups. Studies were commonly of low risk of bias with high quality. Conclusions. Convalescent plasma appears safe but may not reduce mortality in severe influenza. This therapy should be studied within the context of a well designed clinical trial for treatment of SARS Cov 2 infection.
has issue date	2020-02-23(xsd:dateTime)
bibo:doi	10.1101/2020.02.20.20025593
has license	medrxiv
sha1sum (hex)	8d6d3be5f9353eb3358b44e646c83f1a90861b4d
schema:url	https://doi.org/10.1101/2020.02.20.20025593
resource representing a document's title	The efficacy of convalescent plasma for the treatment of severe influenza
resource representing a document's body	covid:8d6d3be5f9353eb3358b44e646c83f1a90861b4d#body_text
is schema:about of	named entity 'CHINA' named entity 'plasma' named entity 'CLINICAL PRACTICE' named entity 'NATIONAL' named entity 'USE' named entity 'PROJECT' named entity 'SEVERE' named entity 'INFLUENZA' named entity 'CLINICAL BENEFIT' named entity 'SCIENCE AND TECHNOLOGY' named entity 'ACUTE' named entity 'ADMINISTRATION' named entity 'MAJOR' named entity 'NATURAL SCIENCE' named entity 'CLEAR' named entity 'EVIDENCE OF' named entity 'MAY BE' named entity 'EVIDENCE' named entity 'RANDOMIZED CONTROLLED TRIALS' named entity 'META-ANALYSIS' named entity 'TO SUPPORT' named entity 'BACKGROUND' named entity 'SYSTEMATIC REVIEW' named entity 'VIRAL' named entity 'ASSESS' named entity 'TREATMENT' named entity 'FOUNDATION' named entity 'RESPIRATORY INFECTIONS' covid:arg/8d6d3be5f9353eb3358b44e646c83f1a90861b4d named entity 'clear' named entity 'evidence' named entity 'evidence based' named entity 'titer' named entity 'coronaviruses' named entity 'convalescent plasma' named entity 'clinical trial' named entity 'influenza' named entity 'MERS-CoV' named entity 'convalescent plasma' named entity 'systematic reviews' named entity 'placebo group' named entity 'medRxiv' named entity 'medRxiv' named entity 'coronaviruses' named entity 'randomized controlled trials' named entity 'meta-analysis' named entity 'convalescent plasma' named entity 'hemagglutination inhibition' named entity 'infection' named entity 'peer-reviewed' named entity 'rate of mortality' named entity 'medRxiv' named entity 'passive immunotherapy' named entity 'cytokine' named entity 'placebo' named entity '0.51' named entity 'preprint' named entity 'mechanical ventilation' named entity 'COVID' named entity 'allocation concealment' named entity 'study population' named entity 'pneumonia' named entity 'National' named entity 'convalescent plasma' named entity 'preprint' named entity 'convalescent serum' named entity 'allocation concealment' named entity 'infection' named entity 'immunoglobulin' named entity 'randomized controlled trials' named entity 'Viral pneumonia' named entity 'preprint' named entity 'Cochrane' named entity 'virus' named entity 'odds ratios' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software